Evommune, Inc. (EVMN)

Evommune Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	61.84	16.26	29.02
Short-Term Investments	24.96	55.79	50.06
Cash & Short-Term Investments	86.8	72.04	79.08
Cash Growth	-	-8.91%	-
Prepaid Expenses	6.6	1.95	0.95
Total Current Assets	94.9	73.99	80.03
Property, Plant & Equipment	1.05	1.8	1.97
Other Long-Term Assets	0.27	0.27	0.25
Total Assets	96.21	76.06	82.25
Accounts Payable	3.67	8.26	1.76
Accrued Expenses	5.92	6.73	4.03
Current Portion of Leases	0.42	0.86	0.77
Current Unearned Revenue	-	3	-
Other Current Liabilities	0.08	9.13	0.3
Total Current Liabilities	10.09	27.98	6.86
Long-Term Leases	0.35	0.52	0.49
Long-Term Deferred Tax Liabilities	-	-	3
Other Long-Term Liabilities	-	0.02	0.25
Total Liabilities	10.44	28.52	10.59
Common Stock	-	0	0
Additional Paid-In Capital	9.11	7.98	6.2
Retained Earnings	-180.34	-152.22	-83.91
Total Common Equity	-171.23	-144.24	-77.71
Shareholders' Equity	85.77	47.54	71.66
Total Liabilities & Equity	96.21	76.06	82.25
Total Debt	0.77	1.38	1.26
Net Cash (Debt)	86.02	70.66	77.83
Net Cash Growth	-	-9.21%	-
Net Cash Per Share	6.68	5.50	7.29
Filing Date Shares Outstanding	13.25	13.25	10.68
Total Common Shares Outstanding	13.25	13.22	10.68
Working Capital	84.8	46.01	73.18
Book Value Per Share	-12.93	-10.91	-7.28
Tangible Book Value	-171.23	-144.24	-77.71
Tangible Book Value Per Share	-12.93	-10.91	-7.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q